Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.79
(
-1.85%
)
Bitcoin
74,054.91
(
0.15%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 86174

Wednesday, 11/11/2009 7:54:46 PM

Wednesday, November 11, 2009 7:54:46 PM

Post# of 257253

I don't see what bearing a different injector will have on a generic Copaxone.

Teva’s “low-volume” formulation might be able to withstand a patent challenge based on its formulation-specific IP, but it’s doubtful (IMO) that third-party payers would deem such a product worthy of a premium price. Hence, I agree that Teva’s low-volume product is inconsequential to the economic upside of generic Copaxone for MNTA.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now